Exact Sciences to Raise $17.6M in Public Offering

The firm will use the proceeds to fund further development of its stool-based DNA colorectal cancer screening product.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories